Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Pharmacyte Biotech Inc
(NQ:
PMCB
)
1.530
+0.050 (+3.38%)
Streaming Delayed Price
Updated: 3:20 PM EDT, Aug 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Pharmacyte Biotech Inc
< Previous
1
2
3
4
Next >
PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
May 21, 2024
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q3 2024
March 19, 2024
PharmaCyte Biotech just reported results for the third quarter of 2024.
Via
InvestorPlace
PMCB Stock Earnings: PharmaCyte Biotech Reported Results for Q2 2024
December 18, 2023
PharmaCyte Biotech just reported results for the second quarter of 2024.
Via
InvestorPlace
PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc.
November 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
PharmaCyte Biotech Provides Corporate Update on Cell-in-a-Box Technology
October 31, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Final Results of Tender Offer
June 15, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
May 11, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
September 26, 2023
On Tuesday, 386 stocks made new 52-week lows.
Via
Benzinga
PharmaCyte Biotech Announces Cash Tender Offer for up to 7,750,000 Shares at $3.25 Per Share
May 11, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Implement Second $10-Million Share Repurchase Plan
February 02, 2023
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital
August 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
July 28, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
July 21, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
July 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
July 11, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
July 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value
June 15, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
June 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value
June 08, 2022
From
PharmaCyte Biotech
Via
Business Wire
PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
June 02, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
May 23, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes
April 27, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
April 22, 2022
Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The company's market cap stands at $37.0 million.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 19, 2022
Gainers Checkmate Pharmaceuticals (NASDAQ:CMPI) shares increased by 331.5% to $10.4 during Tuesday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements
April 19, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial
April 13, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors
April 05, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate
March 22, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights
March 16, 2022
From
PharmaCyte Biotech, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.